Clinical trial tracker

Clinical trial tracker

Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.

Reset

14 registered trials, newest registry update first. Showing only trials linked to Cagrilintide.

TrialCompoundPhaseStatusSponsorEnrolledPrimary completionRegistry updated
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S330May 12, 2027Nov 16, 2026
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT07607587
CagrilintidePhase 1RecruitingNovo Nordisk A/S114Nov 19, 2027Oct 19, 2026
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S3,400Oct 30, 2024Sep 30, 2026
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06131372
CagrilintidePhase 2CompletedNovo Nordisk A/S626Sep 24, 2025Sep 24, 2026
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NCT07010432
CagrilintidePhase 1RecruitingNovo Nordisk A/S144May 3, 2028Sep 10, 2026
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
NCT07184086
CagrilintidePhase 1Active not recruitingNovo Nordisk A/S80Oct 12, 2027Sep 10, 2026
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323161
CagrilintidePhase 3CompletedNovo Nordisk A/S274Sep 9, 2025Sep 9, 2026
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642
CagrilintidePhase 3Active not recruitingNovo Nordisk A/S300May 11, 2027Aug 6, 2026
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540
CagrilintidePhase 3CompletedNovo Nordisk A/S2,734Nov 19, 2025Jul 8, 2026
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
CagrilintidePhase 3CompletedNovo Nordisk A/S809Dec 8, 2025Feb 6, 2026
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT04982575
CagrilintidePhase 2CompletedNovo Nordisk A/S92Jul 7, 2022Dec 23, 2025
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT05016882
CagrilintidePhase 2CompletedNovo Nordisk A/S698Dec 17, 2024Nov 19, 2025
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT03856047
CagrilintidePhase 2CompletedNovo Nordisk A/S706Mar 2, 2020Jul 5, 2024
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03600480
Cagri-Sema, CagrilintidePhase 1CompletedNovo Nordisk A/S96Jun 12, 2020Nov 17, 2021

Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.